Evidence map›Paper›PMID 38129413›Full record

ArticleScientific reports2023

Discovery of 1-(5-bromopyrazin-2-yl)-1-[3-(trifluoromethyl)benzyl]urea as a promising anticancer drug via synthesis, characterization, biological screening, and computational studies.

Yasser Hussein Issa Mohammed, Israa M Shamkh, Nahed S Alharthi, Mohammed A Shanawaz, Hind A Alzahrani, Basit Jabbar, Saba Beigh, Saad Alghamdi, Nada Alsakhen, Elshiekh B Khidir and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 7 countries.

Yasser Hussein Issa MohammedDepartment of Biochemistry, Faculty of Applied Science, University of Hajjah, Hajjah, Yemen. issayasser16@gmail.com.ORCID 0000-0003-1086-7292
Israa M ShamkhBotany and Microbiology Department, Faculty of Science, Cairo University, Giza, Egypt.
Nahed S AlharthiDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences in Al-Kharj, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.
Mohammed A ShanawazDepartment of Public Health, Faculty of Applied Medical Sciences, Albaha University, Albaha, 65431, Saudi Arabia.
Hind A AlzahraniDepartment of Basic Sciences, Faculty of Applied Medical Sciences, Albaha University, Albaha, 65431, Saudi Arabia.
Basit JabbarCentre of Excellence in Molecular Biology, University of the Punjab, Lahore, 53700, Pakistan.
Saba BeighDepartment of Public Health, Faculty of Applied Medical Sciences, Albaha University, Albaha, 65431, Saudi Arabia.
Saad AlghamdiDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia.ORCID 0000-0003-4532-9128
Nada AlsakhenDepartment of Chemistry, Faculty of Science, The Hashemite University, Zarqa, Jordan.
Elshiekh B KhidirDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia.
Hayaa M AlhuthaliDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia.
Taqwa Hafiz Elamin KaramallaFaculty of Medicine, Helwan University, Helwan, Cairo, Egypt.
Amgad M RabieHead of Drug Discovery and Clinical Research Department, Dikernis General Hospital (DGH), Magliss El-Madina Street, Dikernis City 35744, Dikernis, Dakahlia Governorate, Egypt. amgadpharmacist1@yahoo.com.ORCID 0000-0003-3681-114X
Al Baha University · SAUmm al-Qura University · SAAlkermes (Ireland) · IECairo University · EGHashemite University · JOHelwan University · EGPrince Sattam Bin Abdulaziz University · SATaif University · SAUniversity of Sharjah · AEUniversity of the Punjab · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer and different types of tumors are still the most resistant diseases to available therapeutic agents. Finding a highly effective anticancer drug is the first target and concern of thousands of drug designers. In our attempts to address this concern, a new pyrazine derivative, 1-(5-bromopyrazin-2-yl)-1-[3-(trifluoromethyl)benzyl]urea (BPU), was designed via structural optimization and synthesized to investigate its anticancer/antitumor potential. The in-vitro anticancer properties of BPU were evaluated by MTT assay using selected cell lines, including the Jurkat, HeLa, and MCF-7 cells. The Jurkat cells were chosen to study the effect of BPU on cell cycle analysis using flow cytometry technique. BPU exhibited an effective cytotoxic ability in all the three cell lines assessed. It was found to be more prominent with the Jurkat cell line (IC

Indexed as

Antineoplastic AgentsMatrix Metalloproteinase 2Cell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMatrix Metalloproteinase 9MCF-7 CellsMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipUreaAntineoplastic AgentsMatrix Metalloproteinase 2Matrix Metalloproteinase 9Urea

Identifiers

PMID38129413
PMCPMC10739849
OpenAlexW4390054957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.